



A35751-PCT-USA-A (071986.0243)

PATENT

1630/  
D.J.W.  
71

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Günzburg et al. Customer No.: 21003  
Serial No. : 09/610,215 Examiner: David Lambertson  
Filed : July 5, 2000 Group Art Unit: 1636  
For : RECONSTITUTING RETROVIRAL VECTOR (RECON  
VECTOR) FOR TARGETED GENE EXPRESSION

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

June 4, 2004  
Date

Lisa B. Kole  
Attorney Name

35,225  
PTO Reg. No

Lisa B. Kole  
Signature

6/4/04  
Date of Signature

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§1.97 and 1.98, applicants respectfully request that the documents listed below and on the accompanying PTO 1449 be considered by the Examiner and made of record in the above-referenced application. Copies of the listed documents are enclosed.

1. Walter H. Günzburg (2001) "Editorial overview. The importance of being RCR",  
Current Opinion in Molecular Therapeutics 3(5): 437-438;

2. Tabotta et al. (2001) "Genetic reshuffling reconstitutes functional expression cassettes in retroviral vectors", J. Gene Med 3; 418-426;
3. Karavanas et al. (1998) "Cell targeting by murine retroviral vectors", Critical Reviews in Oncology/Hematology 28: 7-30;
4. Walter H. Günzburg et al. (1996) "Retroviral vector targeting for gene therapy", Cytokines and Molecular Therapy 2: 177-184; and
5. Walter H. Günzburg et al. (1996) "Development of retroviral vectors a safe, targeted gene delivery systems", J. Mol. Med 74:171-182.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that the listed documents are material or constitute "prior art." If the Examiner applies the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of the documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should the documents be applied against the claims of the present application.

This Supplemental Information Disclosure Statement is being filed before the mailing date of any final action, a notice of allowance, or an action that closes prosecution and is accompanied by the fee set forth in 37 C.F.R. §1.17(p). If any additional fee is due, or if any overpayment has been made, the Commissioner is also

authorized to charge any such fee or credit any overpayment, to our Deposit Account No. 02-4377. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

BAKER BOTTS LLP




Lisa B. Kole  
Patent Office Reg. No. 35,225

30 Rockefeller Plaza  
44th Floor  
New York, NY 10012-4498

Attorneys for Applicants  
212-408-2500

Form PTO-1449 U.S. Department of Commerce  
(REV. 2-82) Patent and Trademark Office



Atty. Docket No.  
A35751-PCT-USA-A  
(071986.0243)

Serial No.  
09/610,215

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**  
(Use several sheets if necessary)

Applicants  
Günzburg et al.

Filing Date  
July 5, 2000

Group Art Unit  
1636

**U.S. PATENT DOCUMENTS**

*Exam. Init.		Document No.	Date	Name	Class	Subclass	Filing Date ifAppropriate

**FOREIGN PATENT DOCUMENT**

		Document No.			Class	SubClass	Translator Yes No

**OTHER DOCUMENTS (including Author, Title Date, Pertinent Pages, Etc.)**

		Walter H. Günzburg (2001) "Editorial overview. The importance of being RCR", Current Opinion in Molecular Therapeutics 3(5): 437-438.
		Tabotta et al. (2001) "Genetic reshuffling reconstitutes functional expression cassettes in retroviral vectors", J. Gene Med 3; 418-426.
		Karavanas et al. (1998) "Cell targeting by murine retroviral vectors", Critical Reviews in Oncology/Hematology 28: 7-30.
		Walter H. Günzburg et al. (1996) "Retroviral vector targeting for gene therapy", Cytokines and Molecular Therapy 2: 177-184.
		Walter H. Günzburg et al. (1996) "Development of retroviral vectors a safe, targeted gene delivery systems", J. Mol. Med 74:171-182.

Examiner

Date Considered

\* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.